Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Parker H. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA, USA.
Nat Commun. 2021 May 12;12(1):2746. doi: 10.1038/s41467-021-22965-9.
Despite the clinical success of blocking its interactions, how PD-1 inhibits T-cell activation is incompletely understood, as exemplified by its potency far exceeding what might be predicted from its affinity for PD-1 ligand-1 (PD-L1). This may be partially attributed to PD-1's targeting the proximal signaling of the T-cell receptor (TCR) and co-stimulatory receptor CD28 via activating Src homology region 2 domain-containing phosphatases (SHPs). Here, we report PD-1 signaling regulates the initial TCR antigen recognition manifested in a smaller spreading area, fewer molecular bonds formed, and shorter bond lifetime of T cell interaction with peptide-major histocompatibility complex (pMHC) in the presence than absence of PD-L1 in a manner dependent on SHPs and Leukocyte C-terminal Src kinase. Our results identify a PD-1 inhibitory mechanism that disrupts the cooperative TCR-pMHC-CD8 trimolecular interaction, which prevents CD8 from augmenting antigen recognition, explaining PD-1's potent inhibitory function and its value as a target for clinical intervention.
尽管阻断其相互作用在临床上取得了成功,但 PD-1 如何抑制 T 细胞激活仍不完全清楚,其效力远远超过其与 PD-1 配体-1(PD-L1)亲和力的预测值就是一个例证。这可能部分归因于 PD-1 通过激活 Src 同源结构域 2 含磷酸酶(SHPs)来靶向 T 细胞受体(TCR)和共刺激受体 CD28 的近端信号传导。在这里,我们报告 PD-1 信号转导调节初始 TCR 抗原识别,表现在存在 PD-L1 时,T 细胞与肽-主要组织相容性复合物(pMHC)的相互作用中,扩散面积较小,形成的分子键较少,键寿命较短,而在不存在 PD-L1 时则没有这种情况,这种情况依赖于 SHP 和白细胞 C 末端Src 激酶。我们的结果确定了一种 PD-1 抑制机制,该机制破坏了协同的 TCR-pMHC-CD8 三聚体相互作用,从而阻止了 CD8 增强抗原识别,解释了 PD-1 强大的抑制功能及其作为临床干预靶点的价值。